Dana Dlouha1, Milan Blaha2, Vladimir Blaha3, Ilona Fatorova2, Jaroslav A Hubacek4, Petr Stavek4, Vera Lanska5, Alena Parikova6, Jan Pitha7. 1. Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: dadl@ikem.cz. 2. 4th Department of Internal Medicine, Charles University School of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. 3. Department of Gerontology and Metabolism, Charles University School of Medicine and Teaching Hospital, Hradec Králové, Czech Republic. 4. Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 5. Medical Statistical Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 6. Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. 7. Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Internal Medicine, 2nd Medical Faculty, Charles University, Prague, Czech Republic.
Abstract
BACKGROUND: LDL/Lp(a) apheresis therapy is a well-established method of aggressively lowering LDL and Lp(a). Recently, miRNAs have been discussed as markers of vascular status including atherosclerosis. MiRNAs inhibit post-transcriptional processes through RNA duplex formation resulting in gene silencing or regulation of gene expression. MATERIALS AND METHODS: We measured a profile of 175 plasma-circulating miRNAs using pre-defined Serum/Plasma Focus Human microRNA PCR Panels in pooled samples of 11 subjects with familial hypercholesterolaemia under long-term apheresis treatment. Subsequently we analysed expressions of ten pre-selected miRNAs potentially involved in lipid homeostasis in the same group of subjects. We compared plasma-circulating miRNA levels isolated from peripheral blood collected immediately before and after apheresis. RESULTS: The greatest differences in plasma levels were found in miR-451a, miR-16, miR-19a/b, miR-223 and miR-185. In subsequent individual miRNA assay we detected a significant increase in miR-33b levels after apheresis (P < 0.05). Additionally, correlations between plasma lipids and miR-33a (P < 0.04) and miR-122 (P < 0.01) have been determined. Moreover, miR-122 levels in LDLR homozygotes were higher compared to heterozygotes after, but not before, apheresis treatment (P < 0.04). CONCLUSIONS: LDL/Lp(a) apheresis has an impact on miRNAs associated with lipid homeostasis and vascular status.
BACKGROUND: LDL/Lp(a) apheresis therapy is a well-established method of aggressively lowering LDL and Lp(a). Recently, miRNAs have been discussed as markers of vascular status including atherosclerosis. MiRNAs inhibit post-transcriptional processes through RNA duplex formation resulting in gene silencing or regulation of gene expression. MATERIALS AND METHODS: We measured a profile of 175 plasma-circulating miRNAs using pre-defined Serum/Plasma Focus Human microRNA PCR Panels in pooled samples of 11 subjects with familial hypercholesterolaemia under long-term apheresis treatment. Subsequently we analysed expressions of ten pre-selected miRNAs potentially involved in lipid homeostasis in the same group of subjects. We compared plasma-circulating miRNA levels isolated from peripheral blood collected immediately before and after apheresis. RESULTS: The greatest differences in plasma levels were found in miR-451a, miR-16, miR-19a/b, miR-223 and miR-185. In subsequent individual miRNA assay we detected a significant increase in miR-33b levels after apheresis (P < 0.05). Additionally, correlations between plasma lipids and miR-33a (P < 0.04) and miR-122 (P < 0.01) have been determined. Moreover, miR-122 levels in LDLR homozygotes were higher compared to heterozygotes after, but not before, apheresis treatment (P < 0.04). CONCLUSIONS: LDL/Lp(a) apheresis has an impact on miRNAs associated with lipid homeostasis and vascular status.
Authors: J Víšek; M Bláha; V Bláha; M Lášticová; M Lánska; C Andrýs; J Duintjer Tebbens; Ivone Cristina Igreja E Sá; K Tripská; M Vicen; I Najmanová; P Nachtigal Journal: Orphanet J Rare Dis Date: 2021-02-27 Impact factor: 4.123
Authors: Gabriela Loscalzo; Julia Scheel; José Santiago Ibañez-Cabellos; Eva García-Lopez; Shailendra Gupta; José Luis García-Gimenez; Salvador Mena-Mollá; Alfredo Perales-Marín; José Morales-Roselló Journal: Int J Mol Sci Date: 2021-12-28 Impact factor: 5.923
Authors: Dana Dlouha; Milan Blaha; Eva Rohlova; Jaroslav A Hubacek; Vera Lanska; Jakub Visek; Vladimir Blaha Journal: Genes (Basel) Date: 2021-10-12 Impact factor: 4.096